Pharmacokinetics and Pharmacodynamics of Continuous Infusion Meropenem in Overweight, Obese, and Morbidly Obese Patients with Stable and Unstable Kidney Function: A Step Toward Dose Optimization for the Treatment of Severe Gram-Negative Bacterial Infections

Clinical Pharmacokinetics

Volumn 54, Issue 9, 2015, Pages 933-941

  Pai, Manjunath P ^a   Cojutti, Piergiorgio ^b,c   Pea, Federico ^b,c  

^a ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^b SANTA MARIA DELLA MISERICORDIA UNIVERSITY HOSPITAL   (Italy)

^c UNIVERSITY OF UDINE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; MEROPENEM; ANTIINFECTIVE AGENT; THIENAMYCIN DERIVATIVE;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; BODY MASS; BODY SIZE; COMPARTMENT MODEL; CONCENTRATION AT STEADY-STATE; CONTINUOUS INFUSION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EXPOSURE; FEMALE; GRAM NEGATIVE INFECTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MAXIMUM LIKELIHOOD METHOD; MEDICAL RECORD REVIEW; MINIMUM INHIBITORY CONCENTRATION; MORBID OBESITY; OBESITY; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; VOLUME OF DISTRIBUTION; AGED; BAYES THEOREM; DOSE RESPONSE; DRUG ADMINISTRATION; GRAM-NEGATIVE BACTERIAL INFECTIONS; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY; KIDNEY FUNCTION TEST; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BAYES THEOREM; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; INFUSIONS, INTRAVENOUS; KIDNEY; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED; OBESITY; OBESITY, MORBID; OVERWEIGHT; THIENAMYCINS;

EID: 84941169795     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.1007/s40262-015-0266-2     Document Type: Article

References (30)

1. Ng M, Fleming T, Robinson M, et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2014;384(9945):766–81.
2. Hanley MJ, Abernethy DR, Greenblatt DJ. Effect of obesity on the pharmacokinetics of drugs in humans. Clin Pharmacokinet. 2010;49(2):71–87.
3. Wickman C, Kramer H. Obesity and kidney disease: potential mechanisms. Semin Nephrol. 2013;33(1):14–22.
4. Hites M, Taccone FS, Wolff F, et al. Broad-spectrum beta-lactams in obese non-critically ill patients. Nutr Diabetes. 2014;4:e119.
5. Pai MP. Estimating the glomerular filtration rate in obese adult patients for drug dosing. Adv Chronic Kidney Dis. 2010;17(5):e53–62.
6. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31–41.
7. Pea F, Viale P, Cojutti P, et al. Dosing nomograms for attaining optimum concentrations of meropenem by continuous infusion in critically ill patients with severe gram-negative infections: a pharmacokinetics/pharmacodynamics-based approach. Antimicrob Agents Chemother. 2012;56(12):6343–8.
8. ® IV (meropenem for injection) [product label]. Wilmington: Astra Zeneca Pharmaceuticals LP. 2006. http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050706s022lbl.pdf. Accessed 13 Dec 2014.
9. Martinez MN, Papich MG, Drusano GL. Dosing regimen matters: the importance of early intervention and rapid attainment of the pharmacokinetic/pharmacodynamic target. Antimicrob Agents Chemother. 2012;56(6):2795–805.
10. Krueger WA, Bulitta J, Kinzig-Schippers M, et al. Evaluation by monte carlo simulation of the pharmacokinetics of two doses of meropenem administered intermittently or as a continuous infusion in healthy volunteers. Antimicrob Agents Chemother. 2005;49(5):1881–9.
11. Zavascki AP, Carvalhaes CG, Picao RC, et al. Multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii: resistance mechanisms and implications for therapy. Expert Rev Anti Infect Ther. 2010;8(1):71–93.
12. Cohen J. Confronting the threat of multidrug-resistant Gram-negative bacteria in critically ill patients. J Antimicrob Chemother. 2013;68(3):490–1.
13. Franceschi L, Cojutti P, Baraldo M, et al. Stability of generic meropenem solutions for administration by continuous infusion at normal and elevated temperatures. Ther Drug Monit. 2014;36(5):674–6.
14. Manning L, Wright C, Ingram PR, et al. Continuous infusions of meropenem in ambulatory care: clinical efficacy, safety and stability. PLoS One. 2014;9(7):e102023.
15. Carlier M, Stove V, Verstraete AG, et al. Stability of generic brands of meropenem reconstituted in isotonic saline. Minerva Anestesiol. 2015;81(3):283–7.
16. Udy AA, Roberts JA, Boots RJ, et al. Augmented renal clearance: implications for antibacterial dosing in the critically ill. Clin Pharmacokinet. 2010;49(1):1–16.
17. Li C, Du X, Kuti JL, et al. Clinical pharmacodynamics of meropenem in patients with lower respiratory tract infections. Antimicrob Agents Chemother. 2007;51(5):1725–30.
18. Tam VH, Nikolaou M. A novel approach to pharmacodynamic assessment of antimicrobial agents: new insights to dosing regimen design. PLoS Comput Biol. 2011;7(1):e1001043.
19. Tam VH, Schilling AN, Neshat S, et al. Optimization of meropenem minimum concentration/MIC ratio to suppress in vitro resistance of Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2005;49(12):4920–7.
20. Mosteller RD. Simplified calculation of body-surface area. N Engl J Med. 1987;317(17):1098.
21. Pai MP, Paloucek FP. The origin of the “ideal” body weight equations. Ann Pharmacother. 2000;34(9):1066–9.
22. Bauer LA, Edwards WA, Dellinger EP, et al. Influence of weight on aminoglycoside pharmacokinetics in normal weight and morbidly obese patients. Eur J Clin Pharmacol. 1983;24(5):643–7.
23. Janmahasatian S, Duffull SB, Ash S, et al. Quantification of lean bodyweight. Clin Pharmacokinet. 2005;44(10):1051–65.
24. National Heart, Lung, and Blood Institute. Classification of overweight and obesity by BMI, waist circumference, and associated disease risks. https://www.nhlbi.nih.gov/health/educational/lose_wt/BMI/bmi_dis.htm. Accessed 13 Mar 2015.
25. Cheatham SC, Fleming MR, Healy DP, et al. Steady-state pharmacokinetics and pharmacodynamics of meropenem in morbidly obese patients hospitalized in an intensive care unit. J Clin Pharmacol. 2014;54(3):324–30.
26. Roberts JA, Ulldemolins M, Roberts MS, et al. Therapeutic drug monitoring of beta-lactams in critically ill patients: proof of concept. Int J Antimicrob Agents. 2010;36(4):332–9.
27. Kays MB, Fleming MR, Cheatham SC, et al. Comparative pharmacokinetics and pharmacodynamics of doripenem and meropenem in obese patients. Ann Pharmacother. 2014;48(2):178–86.
28. Daikos GL, Markogiannakis A. Carbapenemase-producing Klebsiella pneumoniae: (when) might we still consider treating with carbapenems? Clin Microbiol Infect. 2011;17(8):1135–41.
29. Pea F, Cojutti P, Merelli M, et al. Treatment of consecutive episodes of multidrug-resistant bacterial pleurisy with different aetiology in a heart transplant candidate: proof of concept of pharmacokinetic/pharmacodynamic optimisation of antimicrobial therapy at the infection site. Int J Antimicrob Agents. 2014;44(6):570–1.
30. Hsu AJ, Tamma PD. Treatment of multidrug-resistant Gram-negative infections in children. Clin Infect Dis. 2014;58(10):1439–48.